New Method of mTOR Regulation by TSC2 Modification

Peak revenue. This is NOT a product peak. The asset is a licensable T-cell-engineering modification; per the Lyell LYL273 archetype an academic owner captures an upfront + clinical/regulatory/commercial milestones + low-single-to-low-double-digit royalties on a partner's eventual ACT product, not full product revenue. The $350M figure is a deliberately conservative risk-adjusted licensing-value envelope (upfront + milestone NPV order-of-magnitude, far below Amtagvi's ~$1B autologous-ACT product ceiling) shown only for cohort rNPV consistency — the rNPV is not the decision criterion here, which is why the asset is classified as a partnership_candidate rather than a standalone equity story.

WACC. 15% reflects a preclinical, mechanism-only engineered-T-cell enhancement module with no clinical candidate, no defined indication, and manufacturing/translational uncertainty — above the 12–13% used for de-risked clinical biologics and consistent with the high discount applied to early platform/enabling technologies.

This asset is not a drug. It is a basic-science / enabling discovery from Johns Hopkins: a specific TSC2 phospho-site (Serine 1365) and engineered TSC2 polypeptide variants that, when introduced into therapeutic T cells, tune activated (but not basal) mTORC1 signaling to improve adoptive cell therapy. The supporting evidence is preclinical — Tan/Powell, JCI Insight 2023 — showing that CD8+ T cells carrying the non-phosphorylatable TSC2-S1365A variant gain effector function while retaining memory potential and outperform wild-type cells in murine and human-xenograft solid-tumor models. There is no clinical candidate, no IND, and no defined indication; the JHU listing itself states broad oncology with no single supported indication. Two CMO-level discrepancies are surfaced rather than buried: the pinned modality bucket is gene_therapy, but the true modality is ex vivo genetic engineering of autologous T cells (an enhancement module embedded in a cell-therapy product), and the JHU listing's cited publications (Ranek et al. Circulation 2018; Nature 2019) are the cardiac TSC2-S1365 cardioprotection papers, not the T-cell immuno-oncology work — the cancer-immunotherapy framing rests on the separate Powell JCI Insight 2023 paper.

Economically this is a licensing story, not a product story. Amtagvi (lifileucel) sets the real autologous solid-tumor ACT regulatory and commercial archetype — first-in-class accelerated approval, ~$264M first-full-year revenue, company-stated ~$1B peak potential — and the Lyell/ICT LYL273 deal ($40M upfront + 1.9M shares + $30M clinical + up to $115M regulatory + up to $675M commercial milestones) shows how a clinical-stage engineered-T-cell asset is actually monetized. A preclinical phospho-switch module is several steps earlier than either; FOXO1 stemness reprogramming and Lyell's own Epi-R/Stim-R platform show this is a crowded enhancement-module field where modules frequently fail to convert into products. The engine result is -$60.4M to -$29.2M, with a base rNPV of -$44.8M and cumulative PoS of 3.0%; that wide spread reflects an explicitly hypothetical illustrative envelope shown only for cohort consistency — the rNPV is not the decision criterion here, which is why the asset is classified as a partnership_candidate (royalties + milestones to JHU on a licensee's eventual ACT product), not a standalone equity rNPV.

Verdict: a mechanistically credible, well-published T-cell-engineering enhancement module whose value is licensing optionality into an ACT developer, not a fundable standalone product. It earns rank 22 on the rubric's modality_pos (high gene/cell-therapy modality weight), 0.9 IRA exposure, and a neutral 0.5 whitespace from the 'other' indication — i.e. it scores on modality and breadth, not on being a fundable drug — which is exactly why partnership_candidate, not vc_fundable, is the honest archetype.